3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
28
Burkitt Lymphoma
21
Multiple Myeloma
19
Lymphoma, Large B-Cell, Diffuse
18
Lymphoma, Non-Hodgkin
15
Lymphoma
15
Leukemia, Myeloid, Acute
14
Lymphoma, B-Cell
12
Myelodysplastic Syndromes
11
Lymphoma, Follicular
11
Hodgkin Disease
10
Breast Neoplasms
10
Triple Negative Breast Neoplasms
9
Recurrence
9
Neoplasms
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Ovarian Neoplasms
8
Lymphoma, Mantle-Cell
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Hematologic Neoplasms
7
Sarcoma
6
Osteosarcoma
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Leukemia, Biphenotypic, Acute
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Neuroblastoma
5
Leukemia, Myelomonocytic, Chronic
5
Leukemia
5
Sarcoma, Ewing
4
Rhabdomyosarcoma
4
Interventions
durvalumab
2
Tretinoin
2
Paclitaxel
2
Carboplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Pemetrexed
1
MK 2206
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Cyclophosphamide
×
30 days
×
Clear all
No trials found.